The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Open accessAbstract
Although CRISPR-Cas9 nucleases are widely used for genome editing, the range of sequences that Cas9 can recognize is constrained by the need for a specific protospacer adjacent motif (PAM). As a result, it can often be difficult to target double-stranded breaks (DSBs) with the precision that is necessary for various genome-editing applications. The ability to engineer Cas9 derivatives with purposefully altered PAM specificities would address this limitation. Here we show that the commonly used Streptococcus pyogenes Cas9 (SpCas9) can be modified to recognize alternative PAM sequences using structural information, bacterial selection-based directed evolution, and combinatorial design. These altered PAM specificity variants enable robust editing of endogenous gene sites in zebrafish and human cells not currently targetable by wild-type SpCas9, and their genome-wide specificities are comparable to wild-type SpCas9 as judged by GUIDE-seq analysis. In addition, we identify and characterize another SpCas9 variant that exhibits improved specificity in human cells, possessing better discrimination against off-target sites with non-canonical NAG and NGA PAMs and/or mismatched spacers. We also find that two smaller-size Cas9 orthologues, Streptococcus thermophilus Cas9 (St1Cas9) and Staphylococcus aureus Cas9 (SaCas9), function efficiently in the bacterial selection systems and in human cells, suggesting that our engineering strategies could be extended to Cas9s from other species. Our findings provide broadly useful SpCas9 variants and, more importantly, establish the feasibility of engineering a wide range of Cas9s with altered and improved PAM specificities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [120]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides, there are other variants that could identify different PAM sequences, such as VQR, VRER, VRQR, and QQR1, allowing gene editing on a wider range of genetic loci.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The basic bacterial selection scheme performed was adapted from a previously described positive selection system for identifying Cas9 mutants in E. coli31.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“To be applicable to a wider range of genomic sites, some non-NGG PAM Cas9 were generated.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“This could result in the development of wider-ranged VQR, EQR, and VRER SpCas9 variants, enabling the targeting of NGAN, NGNG, and NGCG PAMs, respectively (Kleinstiver et al., 2015; Hirano et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These modifications have led to the creation of SpCas9 variants such as VQR, EQR, and VRER, which can recognize broader PAM sequences like NGAN, NGNG, and NGCG, respectively (Kleinstiver et al., 2015; Hirano et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [18]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This screen identified four key beneficial point mutations in SpCas9, giving rise to evoCas9, a variant that exhibits fidelity exceeding SpCas9-HF1 and eSpCas9 (Kleinstiver et al., 2015; Casini et al., 2018).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Kleinstiver et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SaKKHcas9 is an evolved variant of SaCas9 and recognizes the more relaxed NNNRRT PAM18.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Base editor screens for in situ mutational scanning at scale
Lue, N. Z., & Liau, B. B. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.009 · Cited by 43
Factors affecting the cleavage efficiency of the CRISPR-Cas9 system
Jung, W. J., Park, S.-J., Cha, S., & Kim, K. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2322054 · Cited by 42
Recent advances in CRISPR-based single-nucleotide fidelity diagnostics
Kohabir, K. A. V., Sistermans, E. A., & Wolthuis, R. M. F. (2025) · Communications Medicine · doi:10.1038/s43856-025-00933-4 · Cited by 39
Diving into marine genomics with CRISPR/Cas9 systems
Momose, T., & Concordet, J. (2016) · Marine Genomics · doi:10.1016/j.margen.2016.10.003 · Cited by 40
Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis
Hong, K., Liu, D., Chen, T., & Wang, Z. (2018) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-018-2537-1 · Cited by 39
CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications
Xu, X., Hulshoff, M. S., Tan, X., Zeisberg, M., & Zeisberg, E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093038 · Cited by 41
Ferdous, M. A., Islam, S. I., Habib, N., Almehmadi, M. M., Allahyani, M. A., Alsaiari, A. A., & Shafie, A. (2022) · Microorganisms · doi:10.3390/microorganisms10102012 · Cited by 38
Genome Editing for Cystic Fibrosis
Wang, G. (2023) · Cells · doi:10.3390/cells12121555 · Cited by 40
Simple, Efficient CRISPR-Cas9-Mediated Gene Editing in Mice: Strategies and Methods
Low, B. E., Kutny, P. M., & Wiles, M. V. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_2 · Cited by 38
Inactivation of Cancer Mutations Utilizing CRISPR/Cas9
Gebler, C., Lohoff, T., Paszkowski‐Rogacz, M., Mircetic, J., Chakraborty, D., Camgöz, A., Hamann, M. V., Theis, M., Thiede, C., & Buchholz, F. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw183 · Cited by 38
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Yang, M., Wei, H., Wang, Y., Deng, J., Tang, Y., Zhou, L., Guo, G. F., & Tong, A. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.05.009 · Cited by 38
Recent advances in plasmid-based tools for establishing novel microbial chassis
Nora, L. C., Westmann, C. A., Guazzaroni, M., Siddaiah, C. N., Gupta, V. K., & Silva‐Rocha, R. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107433 · Cited by 38
Allele-specific genome targeting in the development of precision medicine
Wu, J., Tang, B., & Tang, Y. (2020) · Theranostics · doi:10.7150/thno.43298 · Cited by 43
Retinal gene therapy: an eye-opener of the 21st century
Askou, A. L., Jakobsen, T. S., & Corydon, T. J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0168-2 · Cited by 38
A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing
Yang, L. C., & Chen, J. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.06.003 · Cited by 38
A short overview of CRISPR-Cas technology and its application in viral disease control
Ghorbani, A., Hadifar, S., Salari, R., Izadpanah, K., Burmistrz, M., Afsharifar, A., Eskandari, M. H., Niazi, A., Denes, C. E., & Neely, G. G. (2021) · Transgenic Research · doi:10.1007/s11248-021-00247-w · Cited by 40
Prime Editing: An All-Rounder for Genome Editing
Lu, C., Kuang, J., Shao, T., Xie, S., Li, M., Zhu, L., & Zhu, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179862 · Cited by 43
Current advances of CRISPR-Cas technology in cell therapy
Qiu, H.-Y., Ji, R.-J., & Zhang, Y. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100067 · Cited by 38
Musunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 38
Goel, K., & Ploski, J. E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.914430 · Cited by 41
Requirements for Comprehensive Pharmacogenetic Genotyping Platforms
Lauschke, V. M., & Ingelman‐Sundberg, M. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0023 · Cited by 37
Gee, P., Xu, H., & Hotta, A. (2017) · Stem Cells International · doi:10.1155/2017/8765154 · Cited by 37
CRISPR‐Enabled Tools for Engineering Microbial Genomes and Phenotypes
Tarasava, K., Oh, E. J., Eckert, C. A., & Gill, R. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700586 · Cited by 37
CRISPR/Cas9 Technology: Applications and Human Disease Modeling
Martínez-Lage, M., Torres-Ruiz, R., & Rodríguez, S. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.09.002 · Cited by 40
Revolutionizing male fertility factor research in mice by using the genome editing tool CRISPR /Cas9
Abbasi, F., Miyata, H., & Ikawa, M. (2017) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12067 · Cited by 38
Crystal structure of xCas9 in complex with sgRNA and target DNA (AAG PAM)
Guo, M., Ren, K., Zhu, Y., & Huang, Z. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6aeb/pdb · Cited by 37
CRISPR-Cas systems of lactic acid bacteria and applications in food science
Cui, Y., & Qu, X. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108323 · Cited by 37
CRISPR-M: Predicting sgRNA off-target effect using a multi-view deep learning network
Sun, J., Guo, J. H., & Liu, J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011972 · Cited by 39
Kantor, B., O’Donovan, B., & Chiba‐Falek, O. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102635 · Cited by 38
The expanding footprint of CRISPR/Cas9 in the plant sciences
Schaeffer, S. M., & Nakata, P. A. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1987-x · Cited by 37
Micro RNA s in neutrophils: potential next generation therapeutics for inflammatory ailments
Gurol, T., Zhou, W., & Deng, Q. (2016) · Immunological Reviews · doi:10.1111/imr.12450 · Cited by 36
Application of CRISPR genetic screens to investigate neurological diseases
So, R. W. L., Chung, S., Lau, H. H. C., Watts, J. J., Gaudette, E. V., Al‐Azzawi, Z. A. M., Bishay, J., Lin, L. T., Joung, J., Wang, X., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0343-3 · Cited by 37
Self-citationOn-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 37
Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
Wu, X., Ma, W., Mei, C., Chen, X., Yao, Y., Liu, Y., Qin, X., & Yuan, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01603-0 · Cited by 36
Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain
Ma, S., Wang, X., Hu, Y., Lv, J., Liu, C., Liao, K., Guo, X., Wang, D., Lin, Y., & Rong, Z. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa779 · Cited by 36
Rescue of hearing by adenine base editing in a humanized mouse model of Usher syndrome type 1F
Peters, C. W., Hanlon, K. S., Ivanchenko, M. V., Zinn, E. M., Linarte, E., Li, Y., Levy, J. M., Liu, D. R., Kleinstiver, B. P., Indzhykulian, A. A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.007 · Cited by 36
Self-citationSafety, Security, and Policy Considerations for Plant Genome Editing
Wolt, J. D. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.03.005 · Cited by 37
Impact of Genetic Variation on CRISPR-Cas Targeting
Canver, M. C., Joung, J. K., & Pinello, L. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0016 · Cited by 36
Self-citationCRISPR Genome Engineering for Human Pluripotent Stem Cell Research
Chaterji, S., Ahn, E. H., & Kim, D. (2017) · Theranostics · doi:10.7150/thno.18456 · Cited by 35
Maxwell, C. S., Jacobsen, T. L., Marshall, R., Noireaux, V., & Beisel, C. L. (2018) · Methods · doi:10.1016/j.ymeth.2018.02.016 · Cited by 35
Sanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 38
DNA, RNA, and Protein Tools for Editing the Genetic Information in Human Cells
Chen, X., & Gonçalves, M. A. F. V. (2018) · iScience · doi:10.1016/j.isci.2018.08.001 · Cited by 36
CRISPR/Cas9-targeted removal of unwanted sequences from small-RNA sequencing libraries
Hardigan, A. A., Roberts, B. S., Moore, D. E., Ramaker, R. C., Jones, A. L., & Myers, R. M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz425 · Cited by 37
The ScCas9++ variant expands the CRISPR toolbox for genome editing in plants
Liu, T., Zeng, D., Zheng, Z., Lin, Z., Xue, Y., Li, T., Xie, X., Ma, G., Liu, Y., & Zhu, Q. (2021) · Journal of Integrative Plant Biology · doi:10.1111/jipb.13164 · Cited by 36
Self-citationDevelopment of Light‐Activated CRISPR Using Guide RNAs with Photocleavable Protectors
Jain, P., Ramanan, V., Schepers, A. G., Dalvie, N. S., Panda, A., Fleming, H. E., & Bhatia, S. N. (2016) · Angewandte Chemie · doi:10.1002/ange.201606123 · Cited by 35
Growth-coupled high throughput selection for directed enzyme evolution
Li, Z., Deng, Y., & Yang, G. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108238 · Cited by 34
Self-citationAdvances and perspectives in the application of CRISPR/Cas9 in insects.
Chen, L., Wang, G., Zhu, Y., Xiang, H., & Wang, W. (2016) · PubMed · doi:10.13918/j.issn.2095-8137.2016.4.220 · Cited by 34
The Hypocretin/Orexin Neuronal Networks in Zebrafish
Elbaz, I., Levitas‐Djerbi, T., & Appelbaum, L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_59 · Cited by 34
Ovando-Roche, P., Georgiadis, A., Smith, A. J., Pearson, R. A., & Ali, R. R. (2017) · Current Stem Cell Reports · doi:10.1007/s40778-017-0078-4 · Cited by 35
Emerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9
Nihongaki, Y., Otabe, T., & Sato, M. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04757 · Cited by 35
Application of CRISPR/Cas to Understand Cis- and Trans-Regulatory Elements in Plants
Wolter, F., & Puchta, H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8657-6_2 · Cited by 35
Protein Engineering Strategies to Expand CRISPR-Cas9 Applications
Ribeiro, L. F., Ribeiro, L. F. C., Barreto, M. Q., & Ward, R. J. (2018) · International Journal of Genomics · doi:10.1155/2018/1652567 · Cited by 36
Efficient cleavage resolves PAM preferences of CRISPR-Cas in human cells
Tang, L., Yang, F., He, X., Xie, H., Liu, X., Fu, J., Xi, H., Lu, X., Liu, C., Song, Z., et al. (2019) · Cell Regeneration · doi:10.1016/j.cr.2019.08.002 · Cited by 34
Using CRISPR to understand and manipulate gene regulation
Akıncı, E., Hamilton, M. C., Khowpinitchai, B., & Sherwood, R. I. (2021) · Development · doi:10.1242/dev.182667 · Cited by 36
Engineering Cas9 for human genome editing
Slaymaker, I. M., & Gaudelli, N. M. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.03.004 · Cited by 34
Engineering a PAM-flexible SpdCas9 variant as a universal gene repressor
Wang, J., Teng, Y., Zhang, R., Wu, Y., Lou, L., Zou, Y., Li, M., Xie, Z., & Yan, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-27290-9 · Cited by 35
Functional interrogation of non-coding DNA through CRISPR genome editing
Canver, M. C., Bauer, D. E., & Orkin, S. H. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.008 · Cited by 36
Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology
Schmelas, C., & Grimm, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700432 · Cited by 35
Sung, L., Wu, M., Lin, M., Hsu, M., Truong, V. A., Shen, C., Tu, Y., Hwang, K., Tu, A. P., Chang, Y., et al. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26915 · Cited by 34
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Recent advances in the application of CRISPR/Cas-based gene editing technology in Filamentous Fungi
Li, X.-H., Lu, H., Yao, J.-B., Zhang, C., Shi, T., & Huang, H. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108561 · Cited by 34
Re-engineered RNA-Guided FokI-Nucleases for Improved Genome Editing in Human Cells
Havlicek, S., Shen, Y., Alpagu, Y., Bruntraeger, M., Zufir, N. B. M., Phuah, Z. Y., Fu, Z., Dunn, N. R., & Stanton, L. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.007 · Cited by 33
Enhancing Protein Production Yield from Chinese Hamster Ovary Cells by CRISPR Interference
Shen, C., Sung, L., Lin, S.-Y., Lin, M., & Hu, Y. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00020 · Cited by 33
Harnessing the natural diversity and in vitro evolution of Cas9 to expand the genome editing toolbox
Karvelis, T., Gasiūnas, G., & Šikšnys, V. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.009 · Cited by 33
Wang, Z., Wang, W., Cui, Y. C., Pan, Q., Zhu, W., Gendron, P., Guo, F., Cen, S., Witcher, M., & Liang, C. (2018) · Journal of Virology · doi:10.1128/jvi.01135-18 · Cited by 34
The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook
Lemus, E. H., Reyes-Gopar, H., Enríquez, J. E., & Ochoa, S. (2019) · Genes · doi:10.3390/genes10110865 · Cited by 33
Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a
Swartjes, T., Staals, R. H. J., & John van der, O. O. S. T. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190563 · Cited by 37
Revisiting CRISPR/Cas-mediated crop improvement: special focus on nutrition
Kaul, T., Sony, S. K., Verma, R., Motelb, K. F. A., Prakash, A. T., Eswaran, M., Bharti, J., Nehra, M., & Kaul, R. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00094-7 · Cited by 33
Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Andreana, I., Repellin, M., Carton, F., Kryza, D., Briançon, S., Chazaud, B., Mounier, R., Arpicco, S., Malatesta, M., Stella, B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020278 · Cited by 34
CRISPR/Cas genome editing in grapevine: recent advances, challenges and future prospects
Ren, C., Lin, Y., & Liang, Z. (2022) · Fruit Research · doi:10.48130/frures-2022-0007 · Cited by 37
CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Chadwick, A. C., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309326 · Cited by 33
Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications
Pyzocha, N., & Chen, S. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00800 · Cited by 33
Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape
Ferreira, R., David, F., & Nielsen, J. (2018) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-017-2000-6 · Cited by 33
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
CRISPR Tools for Engineering Prokaryotic Systems: Recent Advances and New Applications
Burbano, D. A., Kiattisewee, C., Karanjia, A. V., Cardiff, R. A. L., Faulkner, I., Sugianto, W., & Carothers, J. M. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100522-114706 · Cited by 34
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 35
Human stem cell-based disease modeling: prospects and challenges
Johnson, J. Z., & Hockemeyer, D. F. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.007 · Cited by 33
A genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 32
Methods for decoding Cas9 protospacer adjacent motif (PAM) sequences: A brief overview
Karvelis, T., Gasiūnas, G., & Šikšnys, V. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.006 · Cited by 32
Precise Cas9 targeting enables genomic mutation prevention
Chavez, A., Pruitt, B. W., Tuttle, M. L., Shapiro, R. S., Cecchi, R. J., Winston, J., Turczyk, B. M., Tung, M., Collins, J. J., & Church, G. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718148115 · Cited by 32
Folkerts, J., Gaudenzio, N., Maurer, M., Hendriks, R. W., Stadhouders, R., Tam, S., & Galli, S. J. (2020) · Nature Protocols · doi:10.1038/s41596-019-0288-6 · Cited by 34
Competitive dCas9 binding as a mechanism for transcriptional control
Anderson, D. A., & Voigt, C. A. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110512 · Cited by 36
Allele-specific silencing of the gain-of-function mutation in Huntington’s disease using CRISPR/Cas9
Shin, J. W., Hong, E. P., Park, S. S., Choi, D. E., Seong, I. S., Whittaker, M. N., Kleinstiver, B. P., Chen, R. Z., & Lee, J. (2022) · JCI Insight · doi:10.1172/jci.insight.141042 · Cited by 37
Self-citationChen, G., Wei, T., Yang, H., Li, G., & Li, H. (2022) · Cells · doi:10.3390/cells11192964 · Cited by 33
Reversing the Central Dogma: RNA-guided control of DNA in epigenetics and genome editing
Chang, H. Y., & Qi, L. S. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.010 · Cited by 33
Improving recombinant protein production in CHO cells using the CRISPR-Cas system
Kalkan, A. K., Palaz, F., Semeniuk, S., Elmousa, N., Ledezma, Y., Cachat, É., & Rios‐Solis, L. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108115 · Cited by 33
Large fragment deletion using a CRISPR/Cas9 system in Saccharomyces cerevisiae
Hao, H., Wang, X., Jia, H., Yu, M., Zhang, X., Tang, H., & Zhang, L. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.07.008 · Cited by 32
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia
Osborn, M. J., Lonetree, C.-L., Webber, B. R., Patel, D., Dunmire, S. K., DeFeo, A. P., McElroy, A. N., MacMillan, M. L., Wagner, J. E., Blazar, B. R., et al. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0149 · Cited by 34
Programmable adenine deamination in bacteria using a Cas9–adenine-deaminase fusion
Zhang, Y. P., Zhang, H., Wang, Z., Wu, Z., Wang, Y., Tang, N., Xu, X., Zhao, S., Chen, W., & Ji, Q. (2020) · Chemical Science · doi:10.1039/c9sc03784e · Cited by 33
Current and Prospective Applications of CRISPR-Cas12a in Pluricellular Organisms
Khan, S., & Sallard, E. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00538-5 · Cited by 31
Targeted genome editing in polyploids: lessons from Brassica
Ahmad, N., Fatima, S., Mehmood, M. A., Zaman, Q. U., Atif, R. M., Zhou, W., Rahman, M., & Gill, R. A. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1152468 · Cited by 31
Robust genome and cell engineering via in vitro and in situ circularized RNAs
Tong, M., Palmer, N. D., Dailamy, A., Kumar, A., Khaliq, H., Han, S., Finburgh, E. N., Wing, M. K., Hong, C., Xiang, Y., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01245-z · Cited by 32
Williams, B. O., & Warman, M. L. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3086 · Cited by 33
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing
Yang, H., Crosby, M., Walker, A., Wei, D. H., Leiker, K., & Weitao, T. (2017) · Journal of Cancer · doi:10.7150/jca.22554 · Cited by 32
Disruptive Technology: CRISPR/Cas-Based Tools and Approaches
Patsali, P., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00391-4 · Cited by 31
Hsu, C., Cheng, Y., Yuan, Y.-H., Hung, W.-F., Cheng, Q., Wu, F., Lee, L., Gelvin, S. B., & Lin, C. (2019) · Plant Molecular Biology · doi:10.1007/s11103-019-00907-w · Cited by 32
Directed Evolution of Plant Processes: Towards a Green (r)Evolution?
Gionfriddo, M., Gara, L. D., & Loreto, F. (2019) · Trends in Plant Science · doi:10.1016/j.tplants.2019.08.004 · Cited by 31
CRISPR-associated nucleases: the Dawn of a new age of efficient crop improvement
Ghogare, R., Williamson-Benavides, B. A., Ramírez-Torres, F. G., & Dhingra, A. (2019) · Transgenic Research · doi:10.1007/s11248-019-00181-y · Cited by 31
Eggenschwiler, R., Gschwendtberger, T., Felski, C., Jahn, C., Länger, F. P., Sterneckert, J. L., Hermann, A., Lühmann, J. L., Steinemann, D., Haase, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01689-2 · Cited by 33
CRISPR Mediated Biosensing Toward Understanding Cellular Biology and Point‐of‐Care Diagnosis
Dai, Y., Wu, Y., Liu, G., & Gooding, J. J. (2020) · Angewandte Chemie · doi:10.1002/ange.202005398 · Cited by 31
Metadata
- Authors
- Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2015-06-22
- Volume
- 523
- Issue
- 7561
- Pages
- 481-485
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4540238
- OpenAlex
- W4245053291
- Semantic Scholar
- afe29e1767b5d0f3563ee9f2c1a586a9d5e8cb9b
- Cited by
- 1,624
- References
- 36
- Citations by year
- 2026: 58 · 2025: 105 · 2024: 117 · 2023: 134 · 2022: 166 · 2021: 165 · 2020: 164 · 2019: 154 · 2018: 147 · 2017: 186 · 2016: 167 · 2015: 58
- FWCI
- 80.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, SpCas9, protospacer adjacent motif, genome editing, off-target effects, SaCas9, Cas9 nickase, zebrafish
- MeSH terms
- Animals, Cell Line, Humans, Mutation, Staphylococcus aureus, Streptococcus pyogenes, Substrate Specificity, Zebrafish, Protein Engineering, Genome, Directed Molecular Evolution, Amino Acid Substitution, Streptococcus thermophilus, Nucleotide Motifs, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
